

Research article

Open Access

Ten-year fatal and non-fatal myocardial infarction incidence in elderly populations in Spain: the EPICARDIAN cohort study

Rafael Gabriel*¹, Margarita Alonso¹, Blanca Reviriego¹, Javier Muñiz², Saturio Vega³, Isidro López², Blanca Novella¹, Carmen Suárez⁴ and Francisco Rodríguez-Salvanés⁴

Address: ¹Unidad de Investigación. Red RECAVA. Hospital Universitario La Paz. Madrid, Spain, ²Instituto Universitario de Ciencias de la Salud. Hospital Juan Canalejo. Red RECAVA. Universidad de La Coruña, Spain, ³Centro de Salud Arévalo. Red RECAVA. Avila, Spain and ⁴Unidad de Hipertensión. Red RECAVA. Hospital Universitario de la Princesa. Madrid, Spain

Email: Rafael Gabriel* - rgabriel.hulp@salud.madrid.org; Margarita Alonso - mgalonso@ceiis.org; Blanca Reviriego - brealmo@terra.es; Javier Muñiz - javmu@udc.es; Saturio Vega - SVEGAQ@telefonica.net; Isidro López - ilopez@medynet.com; Blanca Novella - csuarez.hlpr@salud.madrid.org; Carmen Suárez - csuarez@medynet.com; Francisco Rodríguez-Salvanés - frodriguez.hlpr@salud.madrid.org

* Corresponding author

Published: 24 September 2009

Received: 3 December 2008

BMC Public Health 2009, 9:360 doi:10.1186/1471-2458-9-360

Accepted: 24 September 2009

This article is available from: <http://www.biomedcentral.com/1471-2458/9/360>

© 2009 Gabriel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: In Spain, more than 85% of coronary heart disease deaths occur in adults older than 65 years. However, coronary heart disease incidence and mortality in the Spanish elderly have been poorly described. The aim of this study is to estimate the ten-year incidence and mortality rates of myocardial infarction in a population-based large cohort of Spanish elders.

Methods: A population-based cohort of 3729 people older than 64 years old, free of previous myocardial infarction, was established in 1995 in three geographical areas of Spain. Any case of fatal and non-fatal myocardial infarction was investigated until December 2004 using the "cold pursuit method", previously used and validated by the the WHO-MONICA project.

Results: Men showed a significantly ($p < 0.001$) higher cumulative incidence of myocardial infarction (7.2%; 95%CI: 5.94-8.54) than women (3.8%; 95%CI: 3.06-4.74). Although cumulative incidence increased with age ($p < 0.05$), gender-differences tended to narrow. Adjusted incidence rates were higher in men (957 per 100 000 person-years) than in women (546 per 100 000 person-years) ($p < 0.001$) and increased with age ($p < 0.001$). The increase was progressive in women but not in men. Adjusted mortality rates were also higher in men than in women ($p < 0.001$), being three times higher in the age group of ≥ 85 years old than in the age group of 65-74 years old ($p < 0.001$).

Conclusion: Incidence of fatal and non-fatal myocardial infarction is high in the Spanish elderly population. Men show higher rates than women, but gender differences diminish with age.

Background

Coronary heart disease (CHD) is the main cause of death in the industrialized countries[1], and myocardial infarction (MI) the most dominant manifestation of the disease. In Spain, 11.2% of deaths in males and 9.6% in females were related to CHD in 2005, and more than 85%

MI) the most dominant manifestation of the disease. In Spain, 11.2% of deaths in males and 9.6% in females were related to CHD in 2005, and more than 85%

of annual CHD deaths occur in subjects older than 65 years[2] Although CHD mortality has declined steadily both in men and women[3], it still remains as one of the most frequent causes of mortality[4]

Incidence studies conducted in Spain indicate that CHD is a frequent disease in the general population, with rates in order of 200 new myocardial infarctions per 100,000 men-year and 50 per 100,000 women-year respectively[5] The higher incidence can be observed in the eldest age group. In Spain more than 58% of hospital discharges with the diagnosis of cardiovascular disease are over 65 years and 63% of MI patients admitted to hospitals are over this age[6]. Although higher rates are observed over the age of 65[2], most epidemiological studies still focus on the middle-aged adult population, with scarce representation of the elderly[7]. In fact, age for inclusion used to be limited to 65 years[8] and few studies include subjects older than 74 years[9]. The impact of striking demographic changes in the Spanish elderly population, with an increase of ten million elders during the last decade, and its effect on CHD incidence and mortality needs to be evaluated.

The aim of this paper is to estimate the age- and sex-specific incidence and mortality rates of MI in a cohort of Spanish elders during 10 years of follow-up (1995-2004).

Methods

The EPICARDIAN project is a multicenter, population-based, epidemiological cohort study about cardiovascular diseases in the elderly population of three Spanish areas: Lista district (Madrid city); Arévalo county (Avila); and Begonte county (Lugo). In the urban district of Lista (Madrid city), where the number of registered elders was large (>25.000), we selected an age- and sex-stratified random sample of the population. In the other two study sites (Lugo and Arévalo), all registered elders were invited to the baseline examination. The response rate of the initial cohort selection was 85%. Study design and methods have been previously published[10,11]

Population and design of the study

The original cohort was composed of 3729 subjects older than 65 years old free of previous MI. All participants were followed until the occurrence of the first MI, until death or until 31/12/2004 if alive. Study design, response rates and follow-up information are shown in figure 1.

Field study procedures

The fieldwork was developed into two phases. First phase included a home standard examination, consisting of an interview, physical examination and laboratory tests, in which information on newly developed cardiovascular disease was obtained. Registered nurses were trained and certified in performing the interview. The interview

included questionnaires adapted and validated in Spanish from the MONICA project[12] and the Rose questionnaire on chest pain and dysnea[13]. In 1998 and 2004 this standard examination was repeated using the same contact procedures and methods than in the baseline (1995).

The second phase pertained to the confirmation of CHD events in those individuals who answered affirmatively the questions about coronary disease or angina in the first phase. We used the so called "cold pursuit method" previously used and validated by the MONICA Project, and modified and adapted in Spain by the REGICOR and IBERICA projects[14,15]. In the "cold pursuit method" cases are identified and registered through their discharge. We modified it for pin-pointing and investigating incident cases, employing all of the hospital and primary care clinical records for confirming the cardiovascular event. Causes and dates of death of the deceased individuals in the cohort were also confirmed through the Spanish National Death Index.

Cardiovascular information was requested for all potential lost cases using secondary sources (clinic history, interviewing assigned general practitioner, National Institute of Statistics, mails, and phone calls to the subject or relatives).

Definition of myocardial infarction (MI)


Criterion was based on symptoms, enzyme changes, ECG changes (Minnesota code)[16,17] and post-mortem findings defined in the WHO coding criteria[18] and the validity of the diagnosis was ensured by intra-observer studies[19]

We considered *Definite MI* in those subjects who presented a definite ECG or typical/atypical symptoms, together with a probable ECG and abnormal enzymes, or those with typical symptoms, abnormal enzymes and ischemic ECG.

Possible MI or Coronary Death was considered in those alive subjects with typical symptoms where enzymes and ECG did not allow classification into the definite category, with no evidence of other diagnosis; or death patients with no clear evidence of other cause of death. A Coronary event was considered fatal if death occurred within

28 days of the onset. Under the epigraph "*sudden death*" were included those subjects who died within the first 24 hours from the onset of clinical symptoms, deaths without witness or when the subject was well in the previous 24 hours.

No MI was set in alive patients when the symptoms and diagnostic tests combinations did not allow its classification into the possible MI or when the event could be



-Total No. of CHD cases in 10 years: 305
 -Total alive subjects not interviewed (not localized or rejected) in 10-year follow-up: 31/3729 (16.9%)

Figure 1
Flow-chart EPICARDIAN study (1995-2004). Coronary heart disease (CHD).

explained by means of other causes. In fatal events, MI was rejected when death was related to different clinical diagnosis or autopsy.

Ischaemic cardiac event includes all coronary events that satisfy the criteria for non-fatal definite myocardial infarction or coronary death (fatal definite infarction, fatal possible infarction, or sudden death).

Statistical methods

Basic statistics of centralization (mean, median and its standard deviation and distribution values) were used to describe continuous variables. For the calculation of rates and proportions, the distribution of relative frequencies with confidence intervals at 95% by the Poisson approximated method were used.

To compare proportions the Pearson chi squared test or the chi squared for linear trend for several categories were used. Any value $p < 0.05$ was considered statistically significant. The Kaplan-Meier actuarial method was used in order to estimate the cohort survival and crude incidence rates. Crude incidence rates were standardized for age at baseline by the direct method, using as reference the European population distribution in 2006 as reference[20]

Cumulative incidence is calculated by the number of new cases during the period of study divided by the number of subjects at risk in the population at the beginning of the study. Mortality is the number of deaths in the population. Incidence rate is the number of first fatal and/or non-fatal events per unit of person-time at risk. Mortality rate is the number of fatal events per unit of person-time at risk. Case fatality is the proportion of fatal MI in all MI. Incidence and mortality rates are presented per 100,000 person-years, and case-fatality as a percentage by age at baseline and sex groups for the ten-year follow-up.

Our research is in compliance with the Helsinki Declaration <http://www.wma.net/e/policy/b3.htm>. All participants signed a informed consent at the beginning of the study. The study protocol was approved by the ethics committee of the Hospital Universitario de la Princesa, Madrid.

Results

General characteristics of the initial cohort (n = 3729) and distribution of major cardiovascular risk factors are described in table 1. The initial response rate was 85%. There were 1297 (34.8%) subjects from Lista, 989 (26.5%) from Begonte, and 1443 (38.7%) from Arévalo. The mean age of the cohort at baseline was 74.2 ± 0.4 years (74.43 in women and 73.82 in men). The initial cohort of 3729 subjects accounted for a total 27661 persons-year of follow-up. Median follow-up for the entire cohort was 7.4 years.

In total, 305 CHD events occurred in the entire cohort during the 10-year follow-up period. There were 95 cases of non-fatal definite MI; 101 of fatal definite MI; 51 of possible MI, and 58 of sudden death (table 2). Men showed a higher and significant cumulative incidence of ischemic events ($p < 0.001$); definite MI ($p < 0.001$); fatal ($p < 0.05$) and non-fatal MI ($p < 0.05$); and sudden death ($p < 0.05$) than women. When we analyzed cumulative incidence by age we observed an increased incidence of fatal MI with age ($p < 0.001$) but incidence of non-fatal definite MI did not show a significant increase. The analysis by age, considering the age at the beginning of the study, also showed that men had higher non-fatal cardiovascular risk at earlier ages whereas women described a progressive increase in all cardiovascular risk.

Figure 2 graphically depicts sex and age-related differences in incidence rates (first event) of different acute myocardial infarction diagnostic categories. Rates progressively increase in women but not in men. Men showed similar incidence rates at 65-74 and 75-84 age-groups. Males and females older than 85 years showed the highest incidence rates. Age- standardized incidence rate (per 100 000 person-years) for first definite (fatal and non fatal) MI was

greater in men (957; 95%CI: 899-1019) than in women (546; 95%CI: 514-606) (p < 0.001).

Among the 3729 subjects, 1249 died for any reason during the 10 years of follow-up, which represents a total mortality proportion of 33.5%. The cumulative mortality for CHD, MI or sudden death, was 4.3% (95%CI: 3.6-5.0), higher in men 5.7% (95%CI: 4.6-7.0) than in women 3.2% (95%CI: 2.5-4.0) (p < 0.001); (Table 2). Finally, MI as definite cause of death was confirmed in 58 subjects, which resulted in a specific MI mortality of 2.7% (95%CI: 2.2-3.3). MI mortality rate was also higher in males than in women and particularly among the eldest groups (p < 0.001). Case fatality also increases with age in both genders (p < 0.05) and was higher in men than in women (p < 0.01) (table 3).

Crude CHD mortality rate was 575 per 100 000 person years with higher figures in men (770 per 100 000 person-years) than in women (428 per 100 000 person-years) (p < 0.001). MI mortality rate was 365 (95%CI: 329-404) per 100,000 person-years, greater in men (491; 95%CI: 449-536) than in women (271; 95%CI: 240-305) (p < 0.001). MI adjusted-mortality rates (table 4) were also higher in men (484; 95%CI 442-529) than in women (293; 95%CI 260-329) (p < 0.001). Population aged ≥ 85 years old at baseline reached the highest value with 815 cases per 100.000 person-years, twice compared to 75-84 years old (388 per 100.000 person-years), and three times compared to 65-74 years old (281 per 100.000 person-years) (p < 0.001).

Discussion

This study confirms the magnitude of the impact of MI in the Spanish elderly population, substantially higher than in those younger than 65 years of age[21,22] Elderly men

show higher MI incidence and mortality rates than women, particularly at earlier ages (65-74 years old), but these gender differences tend to narrow as they get older. During the last few years, several epidemiological studies have been initiated in Spain to estimate the MI incidence and mortality. However, they [14,15,23] were limited to middle-age subjects and included scarce number of participants from the eldest groups of age. EPICARDIAN study is the first population-based cohort study in the elderly in Spain, with individual follow-up of study participants for a long period of time (10 years of follow-up). A pilot study reporting the study methods in detail and preliminary results in one (Madrid) of the three areas of the main study have been published recently (11). This cohort has similar socio-demographic characteristics and show a similar cardiovascular risk profile than those described in the scarce the scarce studies carried out in ancients in Spain. There is a Spanish registry, the REGICOR-65 plus[24], that provides information on MI rates in the elderly population of Girona, but the methodology to detect cases is different and only MI cases between 1996 and 1997 were registered, and then it may not represent so accurately the real increase in individual risk as the population get older.

In order to compare our results with other studies we adopted previously used and validated international epidemiological procedures and criteria for the identification and classification of MI[25] Nevertheless, almost all epidemiological studies share similar limitations when trying to identify cardiac events. One important limitation is the difficulty to identify unrecognized MI, which has been described to reach a particularly high proportion in the elderly and postmenopausal women[26] However, we tried to minimize this potential underestimation using multiple specific strategies such as reviewing clinical

Table 1: Demographic characteristics and distribution of major cardiovascular risk factors in the EPICARDIAN study population at baseline (year 1995).

Cardiovascular risk factors		Men n (%) n = 1592	Women n (%) n = 2137	Both n (%) n = 3729
Age group	65-74	975 (61.2)	1228 (57.4)	2203 (59.0)
	75-84	487 (30.6)	692 (32.4)	1179 (31.7)
	> = 85	130 (8.2)	217 (10.2)	347 (9.3)
Hypertension		969 (60,8)	1497 (70,0)	2466 (66,1)
Hypercholesterolemia		347 (21,8)	709 (33,2)	1056 (28,3)
Diabetes		170 (10,7)	254(11,9)	424 (11,4)
Obesity		302 (18,9)	605 (28,3)	907 (24,3)
Smoking		340 (21,4)	69 (3,2)	409 (10,9)

Number of cases and their corresponding percentages (%)
 Hypertension: SBP = 140 mmHg or DBP = 90 mmHg or antihypertensive treatment.
 Diabetes: venous glucose ≥ 126 mg/dl or antidiabetic treatment.
 Hypercholesterolemia: Cholesterol ≥ 250 mg/dL or lipid lowering treatment
 Obesity: Body Mass Index (BMI) ≥ 30 kg/m².
 Smoking: 1 cigarette per day or 5 per week during the last year

Table 2: Cumulative number of cases and risk by sex and age of different CHD diagnostic categories in 10 years of follow-up (1995-2004).

CHD diagnostic Categories		Males				Females				Total (95%CI)	p
		65-74	75-84	<85	All males (95%CI)	65-74	75-84	<85	All females (95%CI)		
Non-fatal definite AMI	No. of events	38	15	3	56	19	14	6	39	95	
	%	3.9	3.1	2.3	3.5 (2.6-4.5) p = 0.53	1.5	2.0	2.8	1.8 (1.3-2.5) p = 0.42	2.5 (2.1-3.1)	<0.05
Possible AMI	No. of events	15	8	2	25	10	12	4	26	51	
	%	1.5	1.6	1.5	1.6 (1.0-2.3) p = 0.8	0.8	1.7	1.8	1.2 (0.8-1.7) p = 0.142	1.4 (1.0-1.8)	0.05
Sudden death	No. of events	13	14	6	33	2	19	4	25	58	
	%	1.3	2.9	4.6	2.1(1.4-2.9) p < 0.05	0.2	2.7	1.8	1.2 (0.7-1.7) p < 0.001	1.6 (1.2-2.0)	<0.001
Fatal and non-fatal definite AMI	No. of events	71	31	12	114	32	32	18	82	196	
	%	7.3	6.4	9.2	7.2(6.0-8.5) p = 0.51	2.6	4.6	8.3	3.8(3.0-4.7) p < 0.001	5.3 (4.6-6.0)	<0.001
Ischemic event	No. of events	99	53	20	172	44	63	26	133	305	
	%	10.2	10.9	15.4	10.8(9.3-12.3) p = 0.2	3.6	9.1	12	6.2 (5.2-7.3) p < 0.001	8.2 (7.3-9.1)	<0.001
Possible and non-fatal definite AMI	No. of events	53	23	5	81	29	26	10	65	146	
	%	5.4	4.7	3.8	5.1(4.0-6.2) p = 0.67	2.4	3.8	4.6	3.0 p = 0.085	3.9 (3.3-4.6)	0.01

CI: Confidence Intervals. "p" represents differences by age and gender. Ischemic event includes all coronary events that satisfy the criteria for non-fatal definite myocardial infarction or coronary death (fatal definite infarction, fatal possible infarction, or sudden death)

reports. Other particular limitation is the possible underestimation of ischemic events, especially during the third period of follow-up (1998-2004), due to the elevated proportion of not contacted subjects (n = 631; 17%). Nevertheless we used secondary sources of information in order to detect possible cases of MI in all of these subjects. It should be also emphasized that the diagnosis of MI was not only based on the ECG, but also on the clinical symptoms and the results of laboratory testing (CK-MB elevations). One might always speculate that the application of more recent diagnostic tools, such as troponin levels, might have revealed a higher proportion of MI cases, as has been estimated by other studies[27] A possible underestimation of the impact of MI in our population can also be explained because of the exclusion of institutionalized

subjects and persons with evidence of relevant disabilities and life threatening diseases.

Once these potential limitations are assumed, the incidence of definite MI seems to be in accordance with other studies carried out in Spain describing higher incidence rates amongst the elderly than rates in middle age-adults. This finding is of crucial importance since elderly people are the fastest growing population segment in western countries and, in consequence, demand for health resources of diagnosis and treatment is bound to increase[28] When comparing our results to those of the REGICOR-65 plus study[24] we observed higher absolute values in our study but both confirm an overall increase with age, and higher risk in men than in women (table 4).





Figure 2
Crude rates by sex and age per 100,000 person-years of different acute myocardial infarction diagnostic categories. *Ischaemic event* definition includes all coronary events that satisfy the criteria for non-fatal definite myocardial infarction or coronary death (fatal definite infarction, fatal possible infarction, or sudden death).

Table 3: Myocardial infarction case fatality by age at baseline and sex among participants. EPICARDIAN (1995-2004)

Gender	Age	Case fatality (95%CI)	No. of events Fatal MI/all MI
Men	65-74	38% (29-49)	33/86
	75-84	41% (27-57)	16/39
	>85	64% (38-86)	9-14
Women	65-74	31% (18-46)	13/42
	75-84	41% (27-55)	18/44
	>85	55% (33-74)	12-22
Total	>65	41% (35-47)	101/247

Values represent proportion with fatal events within each group
 All MI (Myocardial Infarctions): definite and possible
 p for trends (age) <0.05; p (gender) <0.01

Interestingly, in our study, the age-related increase was progressive in women but not in men, and also in accordance with that observed in other studies, in which a concentration of cases occurred in men between 65-74 years in men[29] and over this age in women[15] The question of whether males prematurely develops CHD because a gender related genetic predisposition or whether their occurrence is delayed in women because of a shorter exposure to relevant cardiovascular risk factors arises. The relative higher increase of MI risk with age, observed in elderly females, could be related to the higher burden of cardio-

vascular risk factors described in the postmenopausal women (see table 1).

In the international context, the incidence rates in our study are lower than other European[26,30] and American [31-33] cohort studies (table 4), but age- and sex- distributions are quite similar. This finding can be explained by a real higher MI incidence in north-European and American elderly populations, as it has been described for middle-age adult population in the International MONICA study. Since Spanish elders, as middle-aged adults, show a high prevalence of cardiovascular risk factors[11], the intriguing paradox of a low MI incidence and mortality in southern Europe despite the high cardiovascular risk factor prevalence[34] is likely to hold in older ages.

Men showed a significantly higher CHD mortality compared with that of women, but gender differences are less evident when specific mortality rates (MI rates instead of CHD rates) are considered. A recently published population-based myocardial infarction (MI) register in persons aged 75 to 99 years describes a CHD annual mortality declination among men by 3.5% and 1.0% in the group 75 to 99-years-old. Among women, it declined by 2.2% per year in the 75- to 84-year-old age group but increased by 1.3% per year in the 85- to 99-year-old age group. MI attack rate did not change in men but increased significantly in

Table 4: Incidence rates and mortality rates for acute myocardial infarction (AMI) in different national and international studies carried out in the elderly.

Study Period of Study (Reference No.)	Age Group	All incidence rates		All mortality rates	
		Men	Women	Men	Women
EPICARDIAN Study REGICOR-65 plus (24)*	65-74	981(921-1044) 599(528-670)	351(316-389) 166(131-202)	456(416-499) 220(177-263)	142(120-167) 55(35-75)
	75-84	858(802-917) 972(840-1105)	623(576-673) 409(338-481)	442(402-485) 570(468-672)	350(315-388) 223(170-276)
	>85	1244(1177-1314) 1071(791-1351)	1118(1054-185) 671(307-836)	933(875-994) 740(506-973)	745(693-800) 426(295-558)
	>65	957(898-1018)	546(502-594)	484(442-529)	293(260-329)
EPICARDIAN Study** 1994-2004	>65	957(898-1018)	546(502-594)	484(442-529)	293(260-329)
Oxford Study 1994-95 (30)	65-79	1585	868	826	478
Rotterdam Study 1990-2000 (26)	>55	840(660-1020)1 420(280-550)2	310(230-390)1 360(2.60-450)2		
Bronx Aging Study 1981-89 (31)	>75	4700 (total)		3900 (total)	
Cardiovascular Health Study 1989-90 (32)	>65	2070	790		
Framingham Heart Study 1960-1999 (33)	65-74	1800	800		
	75-84	2700	1400		

**Age- standardization by the European Standard Population (Eurostat 2006) as reference

*New and recurrent cases

¹ recognized myocardial infarction

² unrecognized myocardial infarction

Rates per 100,000 person-years (95% Confidence interval)

women aged 85 to 99 years. [34] Previous research indicates significant age-associated differences in clinical characteristics in elderly patients with AMI, which account for some of the age-associated differences in mortality. Older age is associated with a higher prevalence of co-morbid conditions, atypical AMI presentation, non-diagnostic electrocardiograms, complications and mortality and with significant cardiovascular structural and physiologic changes that might predispose patients to adverse outcomes, including abnormalities of left ventricular diastolic function, decrease in systemic vascular compliance, increased coagulation factors, and altered neurohormonal and autonomic influences. [35]

Lastly, increased fatality with age may be related to lower effectiveness of life-saving treatments, lower hospitalization rates, lower use of diagnostic and therapeutics procedures, longer delay between onset of symptoms and admission to the emergency room and more co-morbidity in the elderly [36-38].

Conclusion

In summary, we conclude that incidence of fatal and non-fatal MI is high in the Spanish elderly population. Overall MI impact remains greater in men compared to women but gender differences tend to narrow as male and female get older. The importance of including older patients in strategies to the prevention and management of MI should be considered

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

-RG was the principal investigator and developed the conception and design, participated in the analysis and interpretation of data, in drafting the manuscript, revising it critically for important intellectual content; and have given final approval of the version to be published.

-MA and BR participated in acquisition of data, analysis and interpretation of data, were involved in drafting the manuscript and have given final approval of the version to be published.

-JM, SV, IL, BN, CS and FRS participated in study design, coordination of field studies, analysis and interpretation of data; have been involved in revising the manuscript critically for important intellectual content; and have given final approval of the version to be published. All authors read and approved the final manuscript.

-EPICARDIAN Group: The members of the group conducted the field studies in each geographical area

Acknowledgements

To Ana Isabel Ortega for writing and editing assistance; to Dr. Carlos Brotons (member of ERICE and RECAVA networks), Prof Jaakko Tuomilehto (University of Helsinki), and Prof. Francisco Fernández-Avilés (coordinator of RECAVA) for reviewing and improving this paper with their comments; to EPICARDIAN Study Group: Rosario Susi García, Guillermo Fernández Jiménez, Cristina Fernández García, JM Ruiz Nodar, Carmen del Arco, Teresa Sáez, Candelas Gómez Mateos, Lourdes de la Rosa Gil, M^a Dolores Montiel Carracedo, Jose Antonio Mendez Fernández, Manuel Javier Garza Vázquez, Isidro Luis Alvarez Choren, Jose Manuel Rabade Cacharon, Teresa Rosalía Pérez Castro. for conducting the field studies.

References

1. American Heart Association: **Heart Disease and Stroke Statistics--2003 Update**. Dallas, Tex: American Heart Association; 2002.
2. Instituto Nacional de Estadística: **Defunciones según la causa de muerte 2005. Tasas de mortalidad por causas (lista reducida), sexo y edad**. *Infarto agudo de miocardio* [<http://www.ine.es>].
3. Banegas JR, Rodríguez F, Villar F, Rey J: **Perspectiva epidemiológica del riesgo cardiovascular en España**. *Iberoamerican Journal of Hypertension* 1996, **1(suppl 2)**:40-45.
4. Murray CL, López A: **Alternative projections of mortality and disability by cause 1990-2020, Global Burden of Disease Study**. *Lancet* 1997, **349**:1498-1504.
5. Medrano MJ, Boix R, Cerrato E, Ramírez M: **Incidence and prevalence of ischaemic heart disease and cerebrovascular disease in Spain: a systematic review of the literature**. *Rev Esp Salud Pública* 2006, **80(1)**:5-15.
6. Instituto Nacional de Estadística: **Encuesta de morbilidad hospitalaria por cardiopatía isquémica en función de la edad**. *España* 2006 [<http://www.ine.es>].
7. Gabriel Sánchez R: **Hacia un estudio epidemiológico sobre factores de riesgo cardiovascular en el anciano en España**. *Rev Esp Geriatr y Gerontol* 1990, **256**:383-388.
8. Ministerio de Sanidad y Consumo: *Plan Integral de Cardiopatía Isquémica 2004-2007*. Madrid 2003.
9. Mc Govern PG, Pankow JS, Sharar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV: **Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors**. *N Engl J Med* 1996, **334**:884-890.
10. Gabriel R, Novella B, Alonso M, Vega S, López I, Suárez C, Muñoz J: **El proyecto Epicardian: un estudio de cohortes sobre enfermedades y factores de riesgo cardiovascular en ancianos españoles: consideraciones metodológicas y principales hallazgos demográficos**. *Rev Esp Salud Pública* 2004, **78**:243-255.
11. Novella B, Alonso M, Rodríguez-Salvanés F, Susi R, Reviriego B, Escalante L, Suárez C, Gabriel R: **Ten-year incidence of fatal and non-fatal myocardial infarction in the elderly population of Madrid**. *Rev Esp Cardiol* 2008, **61**:1140-9.
12. WHO MONICA Project: **MONICA Manual**. 1998 [<http://www.ktl.fi/publications/monica/manual/index.htm>]. URN:NBN:fi-fe1998.1146
13. Rose GA, Blackburn H, Gillyn RF, Prineas RJ: **Métodos de encuesta sobre enfermedades cardiovasculares**. 2nd edition. Ginebra: Organización Mundial de la salud; 1982.
14. Perez G, Pena A, Sala J, Roset P, Masia R, Marrugat J, the REGICOR investigators: **Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992**. *J Epidemiol* 1998, **27**:599-604.
15. Marrugat J, Elosua R, Aldasoro E, Tormo MJ, Vanaclocha H, Segura A, Fiol M, Moreno-Iribas C, Pérez G, Arteagoitia JM, Cirera L, Cabadés A, Vega G, Ayestarán JI, García V, Hurtado-de-Saracho I, García J, Zurriaga O, Muñoz J, Sala J, IBERICA: **Regional variability in population acute myocardial infarction cumulative incidence and mortality rates in Spain 1997 and 1998**. *Eur J Epidemiol* 2004, **19(9)**:831-839.
16. Kennedy RD, Caird FI: **The application of the Minnesota code to population studies of the electrocardiogram in the elderly**. *Gerontologia Clinica* 1972, **14**:5-16.
17. Prineas RJ, Crow RS, Blackburn H: **The Minnesota code manual of electrocardiographic findings: standars and procedures for measurement and clasification**. Bristol: John Wright; 1962.

18. The joint International society and Federation of Cardiology: **World Health Organization Task Force on Standardization of Clinical Nomenclature and Criteria for Diagnosis of Ischemia Heart Disease.** *Circulation* 1979, **59**:607-608.
19. Novella B: **Prevalencia e incidencia de cardiopatía isquémica en ancianos españoles: estudio Epicardian.** In *PhD thesis* Universidad Autónoma de Madrid. Facultad de Medicina, Epidemiología; 2002.
20. Eurostat *Población europea 2006* [<http://ec.europa.eu/eurostat>].
21. Centro Nacional de Epidemiología del Instituto de Salud Carlos III: **Enfermedades cardiovasculares. Casos y tasas anuales ajustadas por edad y por sexo. España 2002** [http://www.isciii.es/hdocs/centros/epidemiologia/epi_cardioisquemica.jsp].
22. Centro Nacional de Epidemiología del Instituto de Salud Carlos III: **Mortalidad por causa, sexo y grupo de edad. 2001** [http://www.isciii.es/hdocs/centros/epidemiologia/anexos/ww9201_ed_cau_tasa.htm].
23. Sans S, Puigdefábregas A, Paluzie G, Monterde D, Balaguer-Vintró I: **Increasing trends of acute myocardial infarction in Spain: the MONICA-Catalonia Study.** *Eur Heart J* 2005, **26**(5):505-515.
24. Marrugat J, Sala J, Manresa JM, Gil M, Elosua R, Perez G, Albert X, Pena A, Masiá R: **Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older.** *Eur J Epidemiol* 2004, **19**:231-237.
25. Tunstall H, Kuulasmaa K, Amouycl P, Arveiler D, Rajakangas A, Pajak A: **Myocardial infarction and coronary death in the World Health Organization MONICA Project.** *Circulation* 1994, **90**:583-612.
26. De Torbal A, Boersma E, Kors JA, van Herpen G, Deckers JW, Kuip DA van der: **Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study.** *Eur Heart J* 2006, **27**(6):729-736.
27. Alfredo Bardaji: **El papel de las troponinas en el diagnóstico y el pronóstico de los síndromes coronarios agudos.** *Rev Esp Cardiol* 2005, **5**:19-25.
28. Krumholz HM: **Ischaemic Heart disease in the elderly.** *Rev Esp Cardiol* 2001, **4**:819-826.
29. Cabadés A: **El registro REGICOR y la epidemiología del infarto de miocardio en España: se hace camino al andar.** *Rev Esp Cardiol* 2007, **60**(4):342-345.
30. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA: **Coronary event and case fatality rates in an English population: results of the Oxford Myocardial Infarction Incidence Study Group.** *Heart* 1998, **80**(1):40-44.
31. Nadelmann J, Frishman WH, Ooi WL, Tepper D, Greenberg S, Guzik H, Lazard EJ, Heiman M, Aronson M: **Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years and older: The Bronx Aging Study.** *Am J Cardiol* 1990, **66**(5):533-537.
32. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, Bovill E, Gottdiener J: **Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: The Cardiovascular Health Study.** *Arch Intern Med* 1999, **159**(12):1339-1347.
33. Cupples LA, D'Agostino RB: **Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. Section 34.** In *The Framingham Study: An Epidemiological Investigation of Cardiovascular disease* Edited by: Kannel WB, Wolf PA, Garrison RJ. Bethesda Md: National Institutes of Health; 1987:87-2703.
34. Koukkunen H, Salomaa V, Lehto S, Ketonen M, Immonen-Räihä P, Lehtonen A, Havulinna A, Kesäniemi YA, Pyörälä K: **FINAMI Study Group. Coronary events in persons aged 75 years or older in Finland from 1995 to the FINAMI study.** *Am J Geriatr Cardiol* 2002, **17**:78-86.
35. Mehta RH, Rathore SS, Radford MJ, Wang Y, Krumholz HM: **Acute myocardial infarction in the elderly: differences by age.** *JACC* 2001, **38**(3):736-741.
36. Mc Govern PG, Pankow JS, Shahar E, Dolinsky K, Folsom A, Blackburn H, Luepker RV, The Minnesota Heart Survey Investigators: **Recent trends in acute CHD-Mortality, Morbidity, Medical Care, and Risk Factors.** *N Engl J Med* 1996, **334**:884-890.
37. Kannel WB, Vokonas PS: **Demographics of the prevalence, incidence, and management of coronary heart disease in the elderly and in women.** *Ann Epidemiol* 1992, **2**:5-14.
38. Bueno H, López-Palop R, Pérez-David E: **Combined effect of age and right ventricular involvement on acute inferior myocardial infarction prognosis.** *Circulation* 1998, **98**:1714-1720.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2458/9/360/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

